The global Infectious Diseases Diagnostics Market is experiencing remarkable growth, with revenues reaching US$ 37 billion in 2024. Projections indicate that the market is on a trajectory to achieve a valuation of US$ 54 billion by the end of 2031, driven by several key factors shaping the industry.
Evidence-based medicine (EBM) is playing a pivotal role in healthcare, enhancing the quality of care, patient satisfaction, and cost-efficiency. EBM emphasizes evidence-driven diagnosis, resulting in a surge in demand for diagnostic kits. Rapid test kits are becoming increasingly essential as the global population grapples with infectious diseases, further boosting market growth.
Next Generation Sequencing
Evidence-based medicine (EBM) is playing a pivotal role in healthcare, enhancing the quality of care, patient satisfaction, and cost-efficiency. EBM emphasizes evidence-driven diagnosis, resulting in a surge in demand for diagnostic kits. Rapid test kits are becoming increasingly essential as the global population grapples with infectious diseases, further boosting market growth.
Next Generation Sequencing
This product will be delivered within 1-3 business days.
Rising Incidence of Infectious Diseases and Focus on Evidence-based Medicine:
The prevalence of infectious diseases, including respiratory ailments and sexually transmitted infections, is surging worldwide. This has led to an imperative need for the diagnosis of these infectious diseases, driving growth in the infectious diseases diagnostics market.Evidence-based medicine (EBM) is playing a pivotal role in healthcare, enhancing the quality of care, patient satisfaction, and cost-efficiency. EBM emphasizes evidence-driven diagnosis, resulting in a surge in demand for diagnostic kits. Rapid test kits are becoming increasingly essential as the global population grapples with infectious diseases, further boosting market growth.
Reliable Test Kits with Low-Cost Solutions:
Efficient diagnostic test kits for infectious diseases are currently in limited supply. The high cost of existing test kits and a lack of accessible diagnostic tools have prompted companies to focus on creating affordable and reliable solutions. Extensive research and development efforts are underway to produce highly accurate and sensitive diagnostic kits, creating new opportunities for market players.Government Initiatives Driving Growth:
Various countries are proactively investing in infectious disease prevention to reduce healthcare costs. For instance, the India Health Fund, in collaboration with the Office of the Principal Scientific Adviser to the Government of India, is soliciting innovations to address urgent issues related to the control, treatment, and cure of infectious diseases. Such initiatives present robust growth prospects for diagnostic kit suppliers.Challenges and Market Constraints:
The presence of numerous market competitors exerts pressure on businesses to lower their prices, affecting the earnings of major international corporations. In addition, the low awareness of rapid diagnostic tests in African nations poses challenges to market penetration. Many developing and underdeveloped countries rely on government funding for rapid diagnostic test kits during epidemics, hindering direct market expansion.Country-wise Insights:
United States Market Boom:
The United States has witnessed a surge in demand for infectious diagnostic tests, particularly in the wake of the COVID-19 pandemic. The increased incidence of chronic diseases has amplified the need for effective rapid medical diagnostic kits, with several companies actively developing and seeking FDA approval for these tests.Lucrative Opportunities in Japan:
Japan, with its strong economy and high living standards, has seen a rise in infectious diseases' incidence. The country's free healthcare services and the authorization of diagnostic kits like Quick Navi - Flu2 have contributed to the expanding infectious diseases diagnostics market.China's Emergence:
China is a prominent player in rapid medical diagnostics, with a multitude of manufacturers producing diagnostic kits that can accurately diagnose various ailments. Advances in multiplexing and profile test kits have accelerated market growth in China.Canada's Growing Demand:
Canada is experiencing an increasing demand for early diagnosis due to the rising complexity of diseases and the need for timely detection. The Public Health Agency of Canada has reported an increase in the use of advanced kits for diagnosing diseases from biological samples, further boosting the infectious diseases diagnostics market.Competitive Landscape:
Manufacturers are striving to develop high-quality diagnostic test kits at competitive prices to expand their market share. Additionally, companies are launching awareness campaigns to educate the public about infectious diseases, thereby increasing demand for their diagnostic test kits.Key Companies Leading the Way:
- The competitive landscape of the Infectious Diseases Diagnostics Market includes key players such as Affymetrix, Inc.
- Ambion, Inc.
- Applera Corporation
- Cenetron Diagnostics
- Cepheid, Inc.
- Chiron Corporation
- Dharmacon, Inc.
- Digene Corporation
- Gen-Probe Incorporated
- Innogenetics NV
- Nanogen, Inc.
- F. Hoffmann-La Roche Ltd
- Becton, Dickinson and Company
- bioMérieux SA
- Hologic, Inc.,
- QIAGEN
- Myriad Genetics, Inc.,
- Thermo Fisher Scientific
- Meridian Bioscience, Inc
Key Segments Covered in Infectious Diseases Diagnostics Industry Research
Product:
- Instrument
- Biochips
- Microfluidics Based POCT
- DNA Microarrays
- Mass Spectrometry
- Real-time Polymerase Chain Reaction (qPCR)
- Fluorescence in situ Hybridization (FISH)
- Sequencing
Next Generation Sequencing
- Kits and reagents
- Kits
- Primary antibodies
- Secondary antibodies
- Substrates
- Buffers
- consumables
Test Type:
- Screening Test
- Diagnostic Test
Application:
- Hospital- Acquired Infections
- Sexually Transmitted Disease (STD)
- Sepsis
- Meningitis
- Respiratory Infections
- HPV
- Gastrointestinal Tract Infections
- Infection in Transplant Patients
- Hepatitis B and C
- Tuberculosis
- Others
End User:
- Hospitals
- Diagnostic Laboratories
- Clinics
- Academic and Research Institutes
- Others
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
Rising Incidence of Infectious Diseases and Focus on Evidence-based Medicine:
The prevalence of infectious diseases, including respiratory ailments and sexually transmitted infections, is surging worldwide. This has led to an imperative need for the diagnosis of these infectious diseases, driving growth in the infectious diseases diagnostics market.Evidence-based medicine (EBM) is playing a pivotal role in healthcare, enhancing the quality of care, patient satisfaction, and cost-efficiency. EBM emphasizes evidence-driven diagnosis, resulting in a surge in demand for diagnostic kits. Rapid test kits are becoming increasingly essential as the global population grapples with infectious diseases, further boosting market growth.
Reliable Test Kits with Low-Cost Solutions:
Efficient diagnostic test kits for infectious diseases are currently in limited supply. The high cost of existing test kits and a lack of accessible diagnostic tools have prompted companies to focus on creating affordable and reliable solutions. Extensive research and development efforts are underway to produce highly accurate and sensitive diagnostic kits, creating new opportunities for market players.Government Initiatives Driving Growth:
Various countries are proactively investing in infectious disease prevention to reduce healthcare costs. For instance, the India Health Fund, in collaboration with the Office of the Principal Scientific Adviser to the Government of India, is soliciting innovations to address urgent issues related to the control, treatment, and cure of infectious diseases. Such initiatives present robust growth prospects for diagnostic kit suppliers.Challenges and Market Constraints:
The presence of numerous market competitors exerts pressure on businesses to lower their prices, affecting the earnings of major international corporations. In addition, the low awareness of rapid diagnostic tests in African nations poses challenges to market penetration. Many developing and underdeveloped countries rely on government funding for rapid diagnostic test kits during epidemics, hindering direct market expansion.Country-wise Insights:
United States Market Boom:
The United States has witnessed a surge in demand for infectious diagnostic tests, particularly in the wake of the COVID-19 pandemic. The increased incidence of chronic diseases has amplified the need for effective rapid medical diagnostic kits, with several companies actively developing and seeking FDA approval for these tests.Lucrative Opportunities in Japan:
Japan, with its strong economy and high living standards, has seen a rise in infectious diseases' incidence. The country's free healthcare services and the authorization of diagnostic kits like Quick Navi - Flu2 have contributed to the expanding infectious diseases diagnostics market.China's Emergence:
China is a prominent player in rapid medical diagnostics, with a multitude of manufacturers producing diagnostic kits that can accurately diagnose various ailments. Advances in multiplexing and profile test kits have accelerated market growth in China.Canada's Growing Demand:
Canada is experiencing an increasing demand for early diagnosis due to the rising complexity of diseases and the need for timely detection. The Public Health Agency of Canada has reported an increase in the use of advanced kits for diagnosing diseases from biological samples, further boosting the infectious diseases diagnostics market.Competitive Landscape:
Manufacturers are striving to develop high-quality diagnostic test kits at competitive prices to expand their market share. Additionally, companies are launching awareness campaigns to educate the public about infectious diseases, thereby increasing demand for their diagnostic test kits.Key Companies Leading the Way:
- The competitive landscape of the Infectious Diseases Diagnostics Market includes key players such as Affymetrix, Inc.
- Ambion, Inc.
- Applera Corporation
- Cenetron Diagnostics
- Cepheid, Inc.
- Chiron Corporation
- Dharmacon, Inc.
- Digene Corporation
- Gen-Probe Incorporated
- Innogenetics NV
- Nanogen, Inc.
- F. Hoffmann-La Roche Ltd
- Becton, Dickinson and Company
- bioMérieux SA
- Hologic, Inc.,
- QIAGEN
- Myriad Genetics, Inc.,
- Thermo Fisher Scientific
- Meridian Bioscience, Inc
Key Segments Covered in Infectious Diseases Diagnostics Industry Research
Product:
- Instrument
- Biochips
- Microfluidics Based POCT
- DNA Microarrays
- Mass Spectrometry
- Real-time Polymerase Chain Reaction (qPCR)
- Fluorescence in situ Hybridization (FISH)
- Sequencing
Next Generation Sequencing
- Kits and reagents
- Kits
- Primary antibodies
- Secondary antibodies
- Substrates
- Buffers
- consumables
Test Type:
- Screening Test
- Diagnostic Test
Application:
- Hospital- Acquired Infections
- Sexually Transmitted Disease (STD)
- Sepsis
- Meningitis
- Respiratory Infections
- HPV
- Gastrointestinal Tract Infections
- Infection in Transplant Patients
- Hepatitis B and C
- Tuberculosis
- Others
End User:
- Hospitals
- Diagnostic Laboratories
- Clinics
- Academic and Research Institutes
- Others
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Market Overview
3. Global Infectious Diseases Diagnostics Market Outlook, 2018 - 2031
4. North America Infectious Diseases Diagnostics Market Outlook, 2018 - 2031
5. Europe Infectious Diseases Diagnostics Market Outlook, 2018 - 2031
6. Asia Pacific Infectious Diseases Diagnostics Market Outlook, 2018 - 2031
7. Latin America Infectious Diseases Diagnostics Market Outlook, 2018 - 2031
8. Middle East & Africa Infectious Diseases Diagnostics Market Outlook, 2018 - 2031
9. Competitive Landscape
10. Appendix
Companies Mentioned
- Affymetrix, Inc.
- Ambion, Inc.
- Applera Corporation
- Cenetron Diagnostics
- Cepheid, Inc.
- Chiron Corporation
- Dharmacon, Inc.
- Digene Corporation
- Gen-Probe Incorporated
- Innogenetics NV
- Nanogen, Inc.
- F. Hoffmann-La Roche Ltd
- Becton, Dickinson and Company
- bioMérieux SA
- Hologic, Inc.,
- QIAGEN
- Myriad Genetics, Inc.,
- Thermo Fisher Scientific
- Meridian Bioscience, Inc.
Methodology
LOADING...
